Corregene Biotechnology Co., Ltd
Clinical trials sponsored by Corregene Biotechnology Co., Ltd, explained in plain language.
-
Custom-Built immune cells take aim at a notorious cancer mutation
Cure OngoingResearchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…
Phase 1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage trial tests a personalized cell therapy for people with advanced colorectal, pancreatic, or lung cancers that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune T cells, engineering them to recognize and attack cancer cells, …
Phase 1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC